Allogene Therapeutics (NASDAQ: ALLO) net income
Allogene Therapeutics reported a net loss of $190.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $257.6m. Earnings per share were −$0.87.
Allogene Therapeutics's best year of the last 8 was fiscal 2021. It reported a loss in 8 of those 8 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$190.9m | — | −7,341.8% | −$0.87 |
| 2024 | −$257.6m | — | −257,590.0% | −$1.32 |
| 2023 | −$327.3m | — | −344,489.5% | −$2.09 |
| 2022 | −$340.4m | — | −218,214.1% | −$2.32 |
| 2021 | −$182.1m | — | −159.6% | −$1.34 |
| 2020 | −$316.4m | — | — | −$2.63 |
| 2019 | −$184.6m | — | — | −$1.83 |
| 2018 | −$211.5m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Allogene Therapeutics net income compared with its sector
By net income for its latest fiscal year, Allogene Therapeutics ranks 404th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Allogene Therapeutics, −7,341.8%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 402nd | Definium Therapeutics | −$183.8m | — |
| 403rd | Glaukos | −$187.7m | −37.0% |
| 404th | Allogene Therapeutics | −$190.9m | −7,341.8% |
| 405th | Sutro Biopharma | −$191.1m | −186.5% |
| 406th | Regenxbio | −$193.9m | −113.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Allogene Therapeutics
- How much did Allogene Therapeutics earn in fiscal 2025?
- Allogene Therapeutics reported a net loss of $190.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $257.6m.
- What are the earnings per share of Allogene Therapeutics?
- They were −$0.87 in fiscal 2025, compared with −$1.32 in fiscal 2024.
- Where does Allogene Therapeutics rank in its sector by net income?
- It ranks 404th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Allogene Therapeutics come from?
- From the annual report (Form 10-K) that Allogene Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Allogene Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Allogene Therapeutics: the Allogene Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.